Theme |
Recent progress in calcium/phosphate metabolism and Klotho |
Title |
Pharmacological effects and application of anti-FGF23 neutralizing antibodies |
Author |
Hisashi Hasegawa |
Pharmacological Research Laboratories, Research Division, Kyowa Hakko Kirin Company, Limited |
[ Summary ] |
Fibroblast growth factor 23 (FGF23) has been determined to be a phosphate-regulating hormone. Several types of hypophosphatemia have recently been reported to be caused by excess FGF23 activity. It was found out that anti-FGF23 neutralizing antibodies ameliorated hypophosphatemic rickets/osteomalacia (XLH) caused by excess FGF23 activity in Hyp mice. Although current therapies for XLH consist of replenishment of phosphates, it is hoped that anti-FGF23 neutralizing antibodies will provide new therapies for XLH, based disease etiology. |